Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Raw Materials (2017 - 2023)

Perspective Therapeutics' Raw Materials history spans 11 years, with the latest figure at $764000.0 for Q3 2023.

  • For Q3 2023, Raw Materials fell 16.23% year-over-year to $764000.0; the TTM value through Sep 2023 reached $764000.0, down 16.23%, while the annual FY2022 figure was $752000.0, N/A changed from the prior year.
  • Raw Materials for Q3 2023 was $764000.0 at Perspective Therapeutics, down from $781000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $912000.0 in Q3 2022 and bottomed at $330000.0 in Q3 2019.
  • The 5-year median for Raw Materials is $645000.0 (2021), against an average of $598105.3.
  • The largest annual shift saw Raw Materials surged 98.69% in 2021 before it dropped 16.23% in 2023.
  • A 5-year view of Raw Materials shows it stood at $372000.0 in 2019, then rose by 20.43% to $448000.0 in 2020, then surged by 67.63% to $751000.0 in 2021, then increased by 0.13% to $752000.0 in 2022, then increased by 1.6% to $764000.0 in 2023.
  • Per Business Quant, the three most recent readings for CATX's Raw Materials are $764000.0 (Q3 2023), $781000.0 (Q2 2023), and $777000.0 (Q1 2023).